公开(公告)号：US20220064740A1

公开(公告)日：2022-03-03

申请号：US17475584

申请日：2021-09-15

Applicant: Exact Sciences Development Company, LLC

Inventor： Manon Van Engeland ,  Manon Adriaan De Bruine ,  Arjan Griffioen ,  Joost Louwagie ,  Katja Bierau ,  Gontran Brichard ,  Gaetan Otto ,  Maarten Penning

IPC: C12Q1/6886

Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases. The invention also relates to methods for identifying, diagnosing, staging or otherwise characterizing cancers, in particular gastrointestinal cancers such as colorectal cancers, gastric cancers and oesophageal cancers. The methods of the invention relate, inter alia, to isolating and analyzing the human DNA component from faecal samples and blood-based samples.

公开(公告)号：US10808286B2

公开(公告)日：2020-10-20

申请号：US15971461

申请日：2018-05-04

Applicant: Exact Sciences Development Company, LLC

Inventor： Manon Van Engeland ,  Manon Adriaan De Bruine ,  Arjan Griffioen ,  Joost Louwagie ,  Katja Bierau ,  Gontran Brichard ,  Gaetan Otto ,  Maarten Penning

IPC: C12Q1/68 ,  C12P19/34 ,  C12Q1/6886

Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases. The invention also relates to methods for identifying, diagnosing, staging or otherwise characterizing cancers, in particular gastrointestinal cancers such as colorectal cancers, gastric cancers and oesophageal cancers. The methods of the invention relate, inter alia, to isolating and analyzing the human DNA component from faecal samples and blood-based samples.

公开(公告)号：US20190032149A1

公开(公告)日：2019-01-31

申请号：US16154023

申请日：2018-10-08

Applicant: Exact Sciences Development Company, LLC

Inventor： Manon Van Engeland ,  Manon Adriaan De Bruine ,  Arjan Griffioen ,  Joost Louwagie ,  Katja Bierau ,  Gontran Brichard ,  Gaetan Otto ,  Maarten Penning

IPC: C12Q1/6886

Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases. The invention also relates to methods for identifying, diagnosing, staging or otherwise characterizing cancers, in particular gastrointestinal cancers such as colorectal cancers, gastric cancers and oesophageal cancers. The methods of the invention relate, inter alia, to isolating and analyzing the human DNA component from faecal samples and blood-based samples.

公开(公告)号：US20180327859A1

公开(公告)日：2018-11-15

申请号：US15971461

申请日：2018-05-04

Applicant: Exact Sciences Development Company, LLC

Inventor： Manon Van Engeland ,  Manon Adriaan De Bruine ,  Arjan Griffioen ,  Joost Louwagie ,  Katja Bierau ,  Gontran Brichard ,  Gaetan Otto ,  Maarten Penning

IPC: C12Q1/6886

Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases. The invention also relates to methods for identifying, diagnosing, staging or otherwise characterizing cancers, in particular gastrointestinal cancers such as colorectal cancers, gastric cancers and oesophageal cancers. The methods of the invention relate, inter alia, to isolating and analyzing the human DNA component from faecal samples and blood-based samples.

公开(公告)号：US09982308B2

公开(公告)日：2018-05-29

申请号：US14613574

申请日：2015-02-04

Applicant: EXACT SCIENCES DEVELOPMENT COMPANY, LLC

Inventor： Manon Van Engeland ,  Manon Adriaan De Bruine ,  Arjan Griffioen ,  Joost Louwagie ,  Katja Bierau ,  Gontran Brichard ,  Gaëtan Otto ,  Maarten Penning

IPC: C12Q1/68 ,  C12P19/34 ,  C07H21/04

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Q2600/16

Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases. The invention also relates to methods for identifying, diagnosing, staging or otherwise characterizing cancers, in particular gastrointestinal cancers such as colorectal cancers, gastric cancers and oesophageal cancers. The methods of the invention relate, inter alia, to isolating and analyzing the human DNA component from fecal samples and blood-based samples.

公开(公告)号：US11149317B2

公开(公告)日：2021-10-19

申请号：US16154023

申请日：2018-10-08

Applicant: Exact Sciences Development Company, LLC

Inventor： Manon Van Engeland ,  Manon Adriaan De Bruine ,  Arjan Griffioen ,  Joost Louwagie ,  Katja Bierau ,  Gontran Brichard ,  Gaetan Otto ,  Maarten Penning

IPC: C12Q1/68 ,  C12P19/34 ,  C12Q1/6886

Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases. The invention also relates to methods for identifying, diagnosing, staging or otherwise characterizing cancers, in particular gastrointestinal cancers such as colorectal cancers, gastric cancers and oesophageal cancers. The methods of the invention relate, inter alia, to isolating and analyzing the human DNA component from faecal samples and blood-based samples.